1242 related articles for article (PubMed ID: 10866316)
1. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Lu H; Waxman DJ
Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
[TBL] [Abstract][Full Text] [Related]
3. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.
Quintieri L; Geroni C; Fantin M; Battaglia R; Rosato A; Speed W; Zanovello P; Floreani M
Clin Cancer Res; 2005 Feb; 11(4):1608-17. PubMed ID: 15746066
[TBL] [Abstract][Full Text] [Related]
4. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
[TBL] [Abstract][Full Text] [Related]
5. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
Grubb MF; Diamond S; Christ DD
Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Baldwin A; Huang Z; Jounaidi Y; Waxman DJ
Arch Biochem Biophys; 2003 Jan; 409(1):197-206. PubMed ID: 12464259
[TBL] [Abstract][Full Text] [Related]
9. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes.
Lewis AD; Lau DH; Durán GE; Wolf CR; Sikic BI
Cancer Res; 1992 Aug; 52(16):4379-84. PubMed ID: 1643634
[TBL] [Abstract][Full Text] [Related]
10. Both cytochromes P450 2E1 and 3A are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P450 2E1.
Zerilli A; Ratanasavanh D; Lucas D; Goasduff T; Dréano Y; Menard C; Picart D; Berthou F
Chem Res Toxicol; 1997 Oct; 10(10):1205-12. PubMed ID: 9348445
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
12. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
Zweers-Zeilmaker WM; Van Miert AS; Horbach GJ; Witkamp RF
Res Vet Sci; 1999 Feb; 66(1):51-5. PubMed ID: 10088712
[TBL] [Abstract][Full Text] [Related]
13. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
14. Expression of cytochromes P450 3A in mouse lung: effects of dexamethasone and pregnenolone 16alpha-carbonitrile.
Haag M; Fautrel A; Guillouzo A; Frossard N; Pons F
Arch Toxicol; 2003 Mar; 77(3):145-9. PubMed ID: 12632254
[TBL] [Abstract][Full Text] [Related]
15. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
Matheny CJ; Ali RY; Yang X; Pollack GM
Drug Metab Dispos; 2004 Sep; 32(9):1008-14. PubMed ID: 15319343
[TBL] [Abstract][Full Text] [Related]
16. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
19. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine.
Diamond S; Rakestraw D; O'Neil J; Lam GN; Christ DD
Drug Metab Dispos; 1994; 22(1):65-73. PubMed ID: 8149892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]